Izuralimab

DB18933InvestigationalProtein Based Therapies

Izuralimab is under investigation in clinical trial NCT05879185 (A Study of Xmab23104 in People With Sarcoma).

Mechanism: Pharmacologically active on Programmed cell death protein 1 and Inducible T-cell costimulator
Curator reviewed
Also known as: IMMUNOGLOBULIN HALF-IG G1-KAPPA/SCFV-H-CH2-CH3, ANTI-(HOMO SAPIENS ICOS (INDUCIBLE T-CELL COSTIMULATORY, ACTIVATION-INDUCIBLE LYMPHOCYTE IMMUNOMEDIATORY MOLECULE, AILIM, CD278)) AND ANTI-(HOMO SAPIENS PDCD1 (PROGRAMMED CELL DEATH 1, PD-1, PD1, CD279)), M · IMMUNOGLOBULIN, ANTI-(HUMAN PROGRAMMED CELL DEATH 1) (HUMAN-MUS MUSCULUS MONOCLONAL XMAB23104 SINGLE-CHAIN VARIABLE FRAGMENT VL-LINKER-VH) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN C-REGION C-TERMINAL FRAGMENT), (260->234'),(263->237')-
Code names: XMAB-23104

Resolves to

Compound

Targets

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Izuralimab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.